Antidepressant Response of DMT Masked With Propofol
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorUniversity Hospital, Basel, Switzerland
About this trial
The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.
Eligibility criteria
Qualifiers
Participants must meet DSM-5 criteria for MDD of at least moderate severity (MADRS≥20).
Participants either currently do not use antidepressants or are treated with a stable dose for at least 4 weeks prior to randomization.
Age ≥ 21 years old.
Sufficient understanding of the German language.
Disqualifiers
Past or present bipolar or psychotic disorder, including depressive disorder with psychotic features.
First-degree relative with a psychotic or bipolar disorder.
Significant prodromal psychotic symptoms (Prodromal Questionnaire-16 symptoms ≥ 6).
Psychiatric condition judged to be incompatible with establishment of rapport with study team members and/or safe exposure to DMT, e.g. diagnosed or suspected borderline personality disorder.
Trial design
Treatments tested in this trial
- N,N-Dimethyltryptamine
- Placebo
- Propofol
- no sedation
Treatment groups
112 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov